We need your support to keep TheyWorkForYou running and make sure people across the UK can continue to hold their elected representatives to account.Donate to our crowdfunder
The Department is aware that supplies of naproxen tablets were limited during January and early February due to a manufacturing issue with the active pharmaceutical ingredient. During this time, we worked closely with all suppliers of naproxen tablets to expedite further deliveries.
Supplies of naproxen tablets are currently available in volumes sufficient to meet national requirements. We will continue to work closely with all manufacturers of naproxen tablets to monitor the overall supply situation to ensure supplies continue to remain available. We have provided updates about the naproxen supply situation to the National Health Service via primary and secondary care networks and will continue to do this.
We understand that naproxen, and other medicines, are vitally important to many people in this country. Our contingency plans include sensible mitigations for medicines that come to the United Kingdom from or via the European Union to ensure that the supply of medicines for patients is not disrupted.
The Department is unable to discuss the specific arrangements for naproxen, because to reassure companies engaging in our contingency plans, we have committed to treating all information received confidentially, securely and to using it only for the purposes of the Department’s programme.
A comprehensive plan has been put in place in the form of a multi-layered approach to minimise any supply disruption:
- buffer stocks and stockpiling (where this is practical) or asking industry to build up buffer stocks in the UK before 29 March;
- buying extra warehouse space for the additional stock to be held in;
- supporting companies in booking space on aircraft for products which require an immediate shipment due to short shelf-life or specific storage conditions;
- making changes to, or clarifications of, certain regulatory requirements so that companies can continue to sell their products in the UK even if we have ‘no deal’; and
- strengthening the processes and resources used to deal with shortages in the event that they do occur.
No one of these measures will work on its own. A combination of securing freight, buffer stocks, stockpiling and warehousing, regulatory flexibility, and clinical assessment and decision making, will be required help to ensure the continuation of medical supplies.
Throughout enacting our plans, the response from pharmaceutical companies has been hugely positive. Companies share our aims of ensuring continuity of medicines’ supply for patients is maintained and able to cope with any potential delays at the border that may arise in the event the UK leaves the EU without a deal.